CC BY-NC-ND 4.0 · J Pediatr Infect Dis 2024; 19(02): 075-082
DOI: 10.1055/s-0043-1777091
Original Article

Suspected Myocarditis after mRNA COVID-19 Vaccination among South Korean Adolescents

Mi Jin Kim
1   Division of Pediatric Cardiology, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Jin Hee Kim
2   Department of Emergency Medicine, Seoul National University Hospital, Seoul, Republic of Korea
Hyun Ok Jun
3   Department of Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
Kyung Min Kim
4   Division of Cardiology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea
5   Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
6   Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
› Author Affiliations
Funding None.


Objective Since vaccination for coronavirus disease 2019 (COVID-19) has been initiated, rare cases of COVID-19 mRNA vaccination-associated myocarditis (VAM) have been reported worldwide. This study aimed to report the short-term outcomes and the clinical presentation of VAM in South Korean adolescents.

Methods In this prospective multicenter study across five tertiary hospitals in South Korea, patients aged 12 to 17 years with symptoms of VAM were included from October 18, 2021, to April 30, 2022. We performed laboratory tests, electrocardiography, chest radiography, echocardiography, and cardiac magnetic resonance imaging studies on these patients.

Results A total of 14 patients were diagnosed with VAM during the study period. The median age of the patients was 15.2 years (interquartile range [IQR], 14.6–15.9) and 11 patients (78.6%) were male. All patients had received a messenger RNA Pfizer-BioNTech COVID-19 vaccine. The median latent period from vaccination to symptom onset was 1 (range, 0–8; IQR, 0.8–3.5) day. Chest pain was the most common symptom (11/14, 78.6%), and the median duration of symptoms was 1 week. Except for one patient (7.1%) who was admitted to intensive care unit, most patients (13/14, 93.8%) had a minor and short clinical course without an intensive treatment including an immune modulator.

Conclusion VAM in South Korean adolescents had self-limiting clinical courses as reported by previous studies. Despite the small number of cases, our findings, consistent with previous studies, revealed that East Asian adolescents might have a similar or even milder clinical course than adolescents of other ethnicities.

Authors' Contribution

J.S.P. conceptualized the study, contributed to formal analysis, software, writing—review and editing. All authors contributed to data curation. M.J.K. contributed to methodology and writing—original draft.

Supplementary Material

Publication History

Received: 02 July 2023

Accepted: 17 October 2023

Article published online:
29 December 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020; 91 (01) 157-160
  • 2 World Health Organization. WHO coronavirus (COVID-19) dashboard. Accessed May 14, 2022 at:
  • 3 Tseng HF, Ackerson BK, Luo Y. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. Nat Med 2022; 28 (05) 1063-1071
  • 4 Pajon R, Doria-Rose NA, Shen X. et al. SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination. N Engl J Med 2022; 386 (11) 1088-1091
  • 5 Fowlkes AL, Yoon SK, Lutrick K. et al. Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5–11 years and adolescents aged 12–15 years—PROTECT Cohort, July 2021–February 2022. MMWR Morb Mortal Wkly Rep 2022; 71 (11) 422-428
  • 6 Frenck Jr RWJ, Klein NP, Kitchin N. et al; C4591001 Clinical Trial Group. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med 2021; 385 (03) 239-250
  • 7 Truong DT, Dionne A, Muniz JC. et al. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after COVID-19 vaccination. Circulation 2022; 145 (05) 345-356
  • 8 Jain SS, Steele JM, Fonseca B. et al. COVID-19 vaccination-associated myocarditis in adolescents. Pediatrics 2021; 148 (05) 148
  • 9 Chin SE, Bhavsar SM, Corson A, Ghersin ZJ, Kim HS. Cardiac complications associated with COVID-19, MIS-C, and mRNA COVID-19 vaccination. Pediatr Cardiol 2022; 43 (03) 483-488
  • 10 Patel T, Kelleman M, West Z. et al. Comparison of multisystem inflammatory syndrome in children-related myocarditis, classic viral myocarditis, and COVID-19 vaccine-related myocarditis in children. J Am Heart Assoc 2022; 11 (09) e024393
  • 11 Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation 2021; 144 (06) 471-484
  • 12 Chua GT, Kwan MYW, Chui CSL. et al. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following Comirnaty vaccination. Clin Infect Dis 2022; 75 (04) 673-681
  • 13 Central Disease Control Headquarters RoK. C. oronavirus (COVID-19),. Republic of Korea. Accessed June 3, 2022 at:
  • 14 Roh DE, Na H, Kwon JE, Choi I, Kim YH, Cho HJ. Chest pain and suspected myocarditis related to COVID-19 vaccination in adolescents-a case series. Children (Basel) 2022; 9 (05) 9
  • 15 Gargano JW, Wallace M, Hadler SC. et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices—United States, June 2021. MMWR Morb Mortal Wkly Rep 2021; 70 (27) 977-982
  • 16 Ferreira VM, Schulz-Menger J, Holmvang G. et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 2018; 72 (24) 3158-3176
  • 17 Oster ME, Shay DK, Su JR. et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA 2022; 327 (04) 331-340
  • 18 Li X, Lai FTT, Chua GT. et al. Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong. JAMA Pediatr 2022; 176 (06) 612-614
  • 19 Kim S, Hwang I, Ko M, Kwon Y, Lee YK. Safety monitoring of COVID-19 vaccination among adolescents aged 12 to 17 years old in the Republic of Korea. Osong Public Health Res Perspect 2022; 13 (03) 230-237
  • 20 Lassale C, Gaye B, Hamer M, Gale CR, Batty GD. Ethnic disparities in hospitalisation for COVID-19 in England: the role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study. Brain Behav Immun 2020; 88: 44-49
  • 21 Williamson EJ, Walker AJ, Bhaskaran K. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584 (7821) 430-436
  • 22 United States government. United States Census. Accessed May 23, 2022 at:
  • 23 Ebinger JE, Achamallah N, Ji H. et al. Pre-existing traits associated with COVID-19 illness severity. PLoS One 2020; 15 (07) e0236240
  • 24 Nakano Y, Kurano M, Morita Y. et al. Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan. Sci Rep 2021; 11 (01) 2776
  • 25 Zhang G, Nie S, Zhang Z, Zhang Z. Longitudinal change of severe acute respiratory syndrome coronavirus 2 antibodies in patients with coronavirus disease 2019. J Infect Dis 2020; 222 (02) 183-188
  • 26 Langton DJ, Bourke SC, Lie BA. et al. The influence of HLA genotype on the severity of COVID-19 infection. HLA 2021; 98 (01) 14-22
  • 27 Dijkstra JM, Frenette AP, Dixon B. Most Japanese individuals are genetically predisposed to recognize an immunogenic protein fragment shared between COVID-19 and common cold coronaviruses. F1000 Res 2021; 10: 196
  • 28 Naemi FMA, Al-Adwani S, Al-Khatabi H, Al-Nazawi A. Association between the HLA genotype and the severity of COVID-19 infection among South Asians. J Med Virol 2021; 93 (07) 4430-4437
  • 29 Yitbarek K, Abraham G, Girma T, Tilahun T, Woldie M. The effect of bacillus Calmette-Guérin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: implications for the COVID-19 pandemic. Vaccine 2020; 38 (41) 6374-6380
  • 30 Thomas SJ, Moreira Jr ED, Kitchin N. et al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med 2021; 385 (19) 1761-1773
  • 31 Yasmin F, Najeeb H, Moeed A. et al. COVID-19 vaccine hesitancy in the United States: a systematic review. Front Public Health 2021; 9: 770985
  • 32 Cui G, Li R, Zhao C, Wang DW. Case report: COVID-19 vaccination associated fulminant myocarditis. Front Cardiovasc Med 2022; 8: 769616
  • 33 He W, Zhou L, Xu K. et al. Immunopathogenesis and immunomodulatory therapy for myocarditis. Sci China Life Sci 2023; 66 (09) 2112-2137
  • 34 Central Disease Control Headquarters RoK. COVID-19 vaccination. Accessed May 18, 2022 at:
  • 35 Our World in Data. C. oronavirus (COVID-19) vaccinations. Accessed May 18, 2022 at:
  • 36 Krug A, Stevenson J, Høeg TB. BNT162b2 vaccine-associated Myo/pericarditis in adolescents: a stratified risk-benefit analysis. Eur J Clin Invest 2022; 52 (05) e13759
  • 37 Guo BQ, Li HB, Yang LQ. Incidence of myopericarditis after mRNA COVID-19 vaccination: a meta-analysis with focus on adolescents aged 12-17 years. Vaccine 2023; 41 (28) 4067-4080
  • 38 Katoto PDMC, Byamungu LN, Brand AS. et al. Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination. NPJ Vaccines 2023; 8 (01) 89